Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SPRUCE BIOSCIENCES, INC. (SPRB)

Spruce Biosciences names Adrian Quartel chief medical officer, replacing interim CMO Kirk Ways

Neutral Impact 3 of 5 leadership Written later

Spruce Biosciences appointed Adrian Quartel, M.D., as its Chief Medical Officer on July 27, 2026, replacing Dr. Kirk Ways, who had been serving as interim Chief Medical Officer. Dr. Ways will remain on the Company's Board of Directors. The filing describes Dr. Quartel's experience in pharmaceutical clinical development and rare disease launches, including prior Chief Medical Officer roles at Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals.

Key points

  • Adrian Quartel, M.D., FFPM, appointed Chief Medical Officer on July 27, 2026
  • Replaces Dr. Kirk Ways, who had been Interim Chief Medical Officer
  • Dr. Ways will continue as a member of the Board of Directors
  • Dr. Quartel previously served as Chief Medical Officer of Zevra Therapeutics, Acer Therapeutics and Adamas Pharmaceuticals

The filing

CompanySPRUCE BIOSCIENCES, INC. (SPRB)
Form8-K, current report
Filed with the SECJul 27, 2026, 8:05 AM ET
Accession number0001193125-26-316928

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.